

美南新聞分類產生 公共欄

美南新聞分類廣告 公告欄

主頁 **scdaily.com** 下方**美南廣告 AD**
是最受歡迎的 **招工/買賣/宣傳** 最佳平台
www.scdaily.com/cia/ClaAD.pdf

只要您已刊登美南新聞分類廣告
即可享有刊登一次『**10元**』的特價活動
請微信: **AD7133021553**
或致電: **281-498-4310**

***美式中餐館**
位6號/290,誠請
全工炒鍋/打雜/接電話
打包/外送員 和
半工周末外送員各一名
需報稅。以上不包住宿。
有意者請電:
713-213-0086
832-593-6688

西北區餐館
位 Cypress 1960
『新優』誠聘
●全工半工接電話
●半工外送員
意者請電:
713-302-0321

餐館請炒鍋
路州 Shreveport
中餐堂吃店,誠請
炒鍋和企台。
意者請電:
832-819-8111
(無人接聽可短信)

糖城餐館請人
Mamak Malaysian
Restaurant. 糖城店,
誠聘企台。新店剛
開張, 新手可以培訓。
環境好, 小費高。電:
346-874-7913
(每週二公休)

餐館請人
位於西北區
誠聘企枱, 炒鍋,
半工外送員.
有意者聯系:
281-966-5342

中餐外賣店
 位於45號南
 新優,誠請
 ● 幫炒 (能炒雙飛)
 ● 打雜兼包外賣
 提供吃住。請電:
713-614-3873

誠聘(中國城)
 ● LVN / RN (PT)
 ● Office Assistant (PT)
 ● 司機 ● 清潔半工
 ● 廚房幫工打雜
 周一到周五
 電: **781-781-9389**
 未接請短信稍後再覆

糖城 HEB 壽司吧 誠招壽司助手 有無經驗均可 意者請電: 832-213-7345	壽司吧急聘 The Sushi Bar is Hiring We are in urgent need of Part-time Sushi Helper in Kroger. 9325 Katy Fwy, Houston, TX 77024. 281-520-6774 (英) 713-299-4129 (中)
---	---

*路州全日餐 Lake Charles 『高薪』誠請 壽司師傅,學徒 廚房師傅,油鍋打雜, 包工全工,意者請電: 832-605-2131	*日餐誠聘 位10號公路,宜家 家私附近,日餐誠請 ●兼職帶位, ●全職或兼職和企檯 需英文流利和可報稅 有意者請電: 832-339-6112
---	--

出售賺錢中餐館 人手不足,位於北休斯頓,離中國城15分鐘,八號邊,一周開6.5天,不送外賣,1500尺,生意4萬2。
適合家庭經營。
歡迎看店議價,請信息
917-951-8859

糖城堂吃外賣店 轉讓。經營多年,生意穩定(周一公休)1490呎,房租便宜,業主還有其他生意管理意者請電:
832-503-0453

中餐館退休轉讓 超過37年賺錢老店 位於休斯外圍 連地及生意一併出售 生意穩定,舍設備 因東主退休出售 意者請電: Kathy 936-662-6412	美式中餐轉讓 外賣堂吃賺錢老餐館 西北白人區 Kroger 超 市旁,離中國城30分鐘 房租便宜, 因缺人手,忍痛轉讓 意者請洽: 非誠勿擾 832-830-3906
--	---

創業良機 在高銷售額的超市內 Sushi Bar 出售 東主退休, 13 年老店, 月營業額 3 萬以上 意者請下午 3 點後電 或簡訊, 歡迎看店: 832-660-2521	KATY 中餐館 出讓 生意佳 意者請電: 917-287-6173
---	--

分類廣告價目表		CLASSIFIED AD. RATE			
週數 Week 格數 Size	一 週 1 wk	二 週 2 wks	三 週 3 wks	一 月 1 mon	
1 格 (1 box)	\$45	\$80	\$105	\$125	
2 格 (2boxes)	\$90	\$160	\$210	\$250	
3 格 (3boxes)	\$135	\$240	\$315	\$375	
4 格 (4boxes)	\$180	\$320	\$420	\$500	
6 格 (6boxes)	\$270	\$480	\$630	\$750	

EFFECTIVE: 從2009年11月1日起實施

千里姻緣 別猶豫，別錯過歲月  一線牽 登廣告專線：281-983-8151	*美國公民(男) 70歲 誠心尋找伴侶 有無身份均可 (可協辦綠卡) 最好有護理經驗,身體強壯. 誠意者請電詳談: 346-277-5978	*美國公民,男 36歲 大學學歷, 廣東人,有正職 誠徵單身女士,先友後婚. 有誠意者電或簡訊: 832-348-6640	徵婚 26歲帥氣男孩,身高186, 研究生再讀,琴棋書畫、儒雅隨和。 誠尋美麗大方女孩, 相攜一生。 聯系電話:346-475-4270
---	--	---	---


 1000 HIRING for Massage 按摩請人	*9年正規床腳店,薪優急聘 位 Memorial 高檔區,離中國城 15 分鐘 高級床腳店,誠徵女按摩師:大費高, 收入穩定,下班早.自駕車,可報稅 有意者請電: 713-468-3799	*7年正規床店請人 45 公路往南方向,36 出口, 離中國城 40 分鐘 全職 6 天,兼職 3~5 天, 提供住宿有廚房, 能做大力有執照者優先。 832-417-4410 (做黃勿擾)	*邊學習邊工作,你的不二選擇! 學按摩賺錢,請來 AATMB 政府認證學校,教資深厚,彈性學習時間 收費合理,中英文授課。 詳情: www.AATMB.com 713-474-5824
---	---	---	--

 按摩服務 Massage Service	*凱悅* 實惠的價格 輕鬆的享受 832-359-6141	 1000 Massage Service 按摩服務	Tiffany SPA 會所 快樂無限 激情有約 美女如雲 技術一流 環境舒適 私屬空間 水床服務 星級享受 越南城 TX 77072 聯系電話：832-941-7212	極品 Baby! 新新新 新人, 高顏值 832-434-9370
---	--	---	---	--

 個人、公司 信用貸款 個人/公司 信用貸款 \$10萬-26萬 無抵押, 無擔保, 信用卡多倍套現 當天兌現, 安全, 合法, 回國資金。 ~~我們幫助您恢復信用~~ 電話: 626-686-8111	美南網站 	入籍班招生 	公民入籍考試輔導班 保證通過 * 由專業入籍考試輔導老師一對一教學輔導 * 提供最新入籍考試基本試題, 模擬考題, 仿真練習, 讓您 100% 通過 * VIP 級別輔導, 時間靈活, 循環輔導, 依照學員的基礎量身定制 * 面試由專業律師陪同 歡迎電話諮詢: 713-815-5011 / 832-279-7772 10700 Richmond Ave, STE 230, Houston, TX 77042
--	--	--	---

 1000 英文班招生 Registration	教授英文&西班牙文 本地美國人,資深英語家庭教師,教授日常美式會話、商業及旅遊用語,個人或集體均可。 *** 協助通過公民考試及移民局面試 *** skype: david.b.browning / Wechat: Teresina1only 832-788-3383 281-587-6912 布朗寧 5338 Beechnut St. Houston, TX 77096 http://davidbrowning.trustab.org	刊登廣告 24小時,微信連絡 AD7133021553	 Piano 鋼琴教學	~ 鋼琴教學 ~ 林老師 MTNA & HMTA 音樂教師會員 超過二十年教學經驗。 學生參加各種比賽,檢定等級考試, 成績皆優異。 學費低廉! 歡迎比較。 電話: 832-235-4374
---	---	--	---	--

 Defensive Driving	謝老師 (MT 駕校) ● 交通安全班 (取消罰單) ● 成人中文筆試: 天天路考 (兩天取得駕照) ● 青少年駕照班 ~~~十八年專業教學經驗~~~ 832-863-8882	1000 駕駛學校  Driving School	美南駕校 疫情期間有中文網絡筆試課, 取消罰單課, 發證書 美南駕校是官方指定考點, 天天有路考。旅遊簽證等各種簽證可以考駕照。青少年班隨時上課。 ● 成人筆試班: 周二, 六 10am-4:30pm ● 取消罰單安全班: 周六, 周日有課 7001 Corporate Dr #203 832-277-7226 王教練	DPS 指定王朝駕校路考第三考場 DPS 路試考官, 全權下放至百利駕校教練上路試 在本校一天可完成筆試, 取得 permit 後可安排路考, 不用排隊等 30 天 ● 筆試班: 每星期一至六上課, 務必預約。 ● 路考班: 務必預約。 考路試, 務必預約。 ● 安全班: 隨時開課。 開課, 務必預約。 電話: 832-633-5555 周師傅 832-983-9509 Tom 發哥
--	---	---	--	---

房產經紀人 Realtor	 房地產經紀人 Kate Zhang ● 個人房屋買賣 ● 商業房產買賣 微信: 15042558967 電/短信: 917-378-5316	 W-2 TAX 報稅	***** 報稅 ***** ● 報個人稅, 公司稅 ● 公司做帳 地址: 美國財富會計樓 6348 Corporate Dr, Houston, TX 77036 打電話或短信: 917-378-5316	 Gun License 申請帶槍執照
報稅服務			德州帶槍執照 中國城軍火庫 可在全美38州攜帶 全課程半天完成\$100 (外州駕照可申請) 各式槍枝買賣/交換 9896 Bellaire #G1 (黃金廣場內) 281-236-4723	

 FOR SALE 車輛買賣 Car for sale	專收購舊車壞車 舊、壞車 動或不動 一律高價收購 中英粵越。電話： 713-482-9267	800  機場接送 Transportation	北夏接送服務 機場、碼頭，一切接送 誠信可靠，安全準時。 保證最低價。有4人7人座服務 832-382-5645	 跌打傳人中醫 坐骨神經，肩周炎	武林跌打傳人中醫 跌打損傷 專精：坐骨神經痛、肩周炎 一次治療基本痊癒，唯我獨尊。 7001 Corporate Dr #213A, Houston 請電：713-772-0300
--	---	---	---	--	--

恆豐裝修公司 台灣專業,政府註冊, 承接:舊屋翻新,水櫃,籬笆, 涼棚,屋頂翻新,棉漏,廚櫃 安裝,木工隔間,磁磚,實木 樓梯,木地板,廚浴改建, 內外油漆,屋內外全部工程 832-366-7510 洪(國台)	浙江大余裝修 公司,住宅,地板,地磚, 內外油漆,廚浴改建, 鋪草皮,修換圍欄 餐廳翻新,高壓沖洗, 大小工程, 價格合理,質量保證。 余: 929-392-5818 eng: 646-925-9275	榮盛裝修 商業住宅,水電木工, 地磚地板,浴室櫥櫃, 內外油漆,大理石安裝, 小修小補。 質量第一,誠信價優! 請電: Sam 劉 832-606-7672	木易裝修 承接房屋大小工程 舊屋翻新,廚房浴室 地板瓷磚,水電木工 涼棚圍欄,高壓清洗 價格公道,免費估價 歡迎來電諮詢:楊 909-800-8876	蘇揚建築裝潢 價格公道,質量保證 房屋,廚房,衛生間裝修 地板,磁磚,大理石面安裝 電氣線,鐵欄杆安裝維修 車庫門,自動門安裝維修 水電,空調,裝修維修 832-607-7861 張 ●誠請裝修工人	永發裝修公司 政府註冊,百萬保險。 30年經驗,一條龍服務 承接:商業/餐館/住宅 精通土木,地板,水電,油漆 保修一年,價格公道, 經驗豐富,保證質量。 646-713-4928 吳 832-207-2626	天天裝修 舊房翻新,內外油漆, 地板地磚,衛浴改建, 櫥櫃台面,柵欄改建, 高壓衝洗,室內清潔。 價格合理,質量保證 提供商業保險 招熟練工人,需有合法 身份,新酬優厚 713-371-2713 戴師傅	吳氏專業裝修 執照# LI 0019006 庭園灑水,庭園設計,籬笆 內外油漆翻新,涼棚涼椅 洗衣機,乾衣機,洗碗機, 水龍頭,地板,地磚,廁浴, 更新,水務維修,電路修換。 832-818-3185 粵粵語
--	--	---	--	---	--	--	---

華美裝修 舊屋翻新, 地板地磚 內外油漆, 廚衛屋頂 籬笆車道, 小修小補 高壓清洗, 各種雜活 ~~價格優惠~~ 832-314-6475	誠實裝修 內外油漆, 屋頂補漏 水電木工, 籬笆水槽. 安裝更換熱水爐. 多年經驗, 價格合理, 質量保證. 請電: 361-460-4530 832-866-2876	潮江裝修 廚廁改建, 地板磁磚 內外油漆, 木工水電 廚櫃理石, 檯面安裝 香港師傅, 專業守信 請電: 陳師傅 832-629-2688 誠聘裝修師傅	順發裝修 地板人工 90 c /呎 地磚磁磚, 紗窗紗門, 換熱水爐, 室內外油漆 二樓樓梯圍欄, 精優價廉. 以上工程, 保修 2 年. (訂做按摩床) 281-323-9938 王順	隨叫隨到裝修 專業漏雨 屋頂翻新 室內外裝修 20 年經驗 免費估價. 大小工程, 百萬保險 346-383-1087 713-269-9582	廣東和記裝修 大小工程, 油漆間隔, 泥水木工, 地板門窗, 天面地台, 廚房浴室, 水電修理, 通 坑 渠. 免費估價, 價廉保質. 832-909-3658 粵 832-909-3686 國	正翔屋頂/裝修 專業住家, 屋頂換新 房屋翻修, 廚浴改建 商業住家, 水電維修 內外油漆, 籬笆車道 灑水系統, 經驗豐富 832-998-5898 王 (國/台語)	700  修理業務 Remodeling
---	--	---	--	--	---	---	--

專做居家小活 修補牆面、油漆、 翻新衛生間、廚房、房間改造,疏通上下水 更換熱水器、漏水、庭院等等.... 居家小活統統都做。 713-429-2685 702-888-5518	誠信裝修 大理石、廚櫃、衛生間改建,磁磚、地板、 內外油漆,涼棚,圍欄及屋頂漏雨, 工廠訂做,塑鋼門窗,雙層玻璃(特約) 工廠直銷 實木地板,復合地板,塑膠地板。 專業屋頂,噴花,保溫棉,質量第一,誠信為本, 土木建築專業,保修二年。●請裝修師傅 歡迎來電：832-630-1850 田師傅	佳寶建築公司 本公司是一家大型建築公司 擁有各類大型建築設備及水電A/C等... 專業執照,施工團隊。 專精大型倉庫,Shopping Center等大型建築 從選址,設計,請照,施工一條龍服務。 百萬保險+質量保證+價格最低 聯系電話：281-886-8888	宏達建築裝修公司 政府註冊.百萬保險.15年經驗 承接：商業/住宅 的 翻新與改造等工程。 誠信為本價格公道，另招裝修師傅 中英 Andy 801-739-5866 中 蘇師傅 832-359-2367
---	---	---	---

美滿裝修 22年經驗,專精商業住宅 理石廚櫃,地板,磁磚,浴室改建,內外油漆, 門窗,水電,涼棚,圍欄及屋頂翻新. 誠信+優惠+專業 特價 & 保修二年 832-419-5588張 ●另請工人	三好裝修 誠信專業的木工和泥瓦工師傅 為您提供裝修服務: 安裝櫥櫃大理石,瓷磚地板,木柵欄和油漆. ~~好技術、好質量、好價錢~~ 聯系電話: 832-778-0090 / 832-289-2279	裝修設計  Remodeling	兄弟建築公司 832-860-1133 承接各類餐廳,美容院,奶茶店,辦公室,廠房等設計,施工建造, 及住宅維修和翻新,免費估價. 最低成本,最佳質量,百萬保險! 選址: 商業租賃,為您的生意精選最佳地點,最旺鋪位. 設計: 施工圖, 3D 效果圖設計,申請施工 PERMIT. 建造: 裝修裝潢,專業執照工程隊伍施工,品質保障. 6100 Corporate Dr. Ste 315, Houston www.usbrothersconstruction.com 
--	--	---	---



If you would like to share news or information with our readers, please send the unique stories, business

news organization events, and school news to us including your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com or contact
John Robbins 281-965-6390
Jun Gai 281-498-4310

Publisher: Wea H. Lee
President: Catherine Lee
Editor: John Robbins

Address: 11122 Bellaire Blvd., Houston, TX 77072
E-mail: News@scdaily.com

Pandemic Cancels Texas African Business Summit



Inside C2

Southern DAILY

Make Today Different

Southern Daily News is published by Southern News Group Daily

Wednesday, December 15 2021

Pfizer shot less effective in South Africa after Omicron emerges, study shows



Vials labelled “VACCINE Coronavirus COVID-19” and a syringe are seen in front of a displayed Pfizer logo in this illustration taken December 11,

JOHANNESBURG, Dec 14 (Reuters) - Pfizer-BioNTech’s COVID-19 vaccine has been less effective in South Africa at keeping people infected with the virus out of hospital since the Omicron variant emerged last month, a real-world study published on Tuesday showed.

Between Nov. 15 and Dec. 7, people who had received two doses of the shot had a 70% chance of avoiding hospitalisation, down from 93% during the previous wave of Delta infections, the study showed. When it came to avoiding infection altogether, the study by South Africa’s largest private health insurance administrator, Discovery Health, showed that protection against catching COVID-19 had slumped to 33% from 80% previously.

The findings from the real-world analysis are some of the first about the protection vaccines offer against Omicron outside of laboratory studies, which have so far shown a reduced ability to neutralise the virus.

The study results were based on an analysis by Discovery’s (DSYJ.J)

clinical research and actuarial teams in collaboration with the South African Medical Research Council (SAMRC).

South Africa alerted the world to Omicron in November, triggering alarm that it could cause another surge in global infections and leading to travel curbs on southern Africa. South Africa’s daily infections have since risen to more than 20,000, with 35% of tests coming back positive in figures reported on Tuesday, and a further 600 hospital admissions and 24 deaths. The South African study was based on more than 211,000 COVID-19 test results of which 78,000 were attributed to Omicron, the variant labelled “of concern” by the World Health Organization and reported in more than 60 countries.

The 78,000 cases were attributed to Omicron based on the relative prevalence of the variant within the country over the study period, but because they have not been confirmed as being the new variant the study cannot offer conclusive findings.

South African scientists sent 630 positive COVID-19 tests for genome sequencing in November to see if they were Omicron

and another 61 so far in December. Last month, 78% were confirmed as Omicron and all 61 this month were the new variant.

‘CONFOUNDING FACTOR’

Discovery cautioned that the study’s findings should be considered preliminary. Michael Head, senior research fellow in global health at the University of Southampton, also said there was a large degree of uncertainty for now about Omicron.

“It is important to avoid inferring too much right now from any national scenario. For example, the narrative around South Africa is that Omicron may be much milder, whereas reports out of Denmark broadly suggests the opposite,” he said.

South Africa is using the Pfizer-BioNTech (PFE.N), and Johnson & Johnson (JNJ.N) vaccines in its immunisation campaign, with more than 20 million Pfizer doses administered so far.

J&J and the SAMRC are conducting a large real-world study of J&J’s vaccine and recent analysis has shown no deaths

from Omicron, SAMRC President Glenda Gray said.

Vials labelled “VACCINE Coronavirus COVID-19” and a syringe are seen in front of a displayed Pfizer logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration
A healthcare worker administers the Pfizer coronavirus disease (COVID-19) vaccine to a man, amidst the spread of the SARS-CoV-2 variant Omicron, in Johannesburg, South Africa, December 9, 2021. REUTERS/Sumaya Hisham/File Photo
Vials labelled “VACCINE Coronavirus COVID-19” and a syringe are seen in front of a displayed Pfizer logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration
A healthcare worker administers the Pfizer coronavirus disease (COVID-19) vaccine to a man, amidst the spread of the SARS-CoV-2 variant Omicron, in Johannesburg, South Africa, December 9, 2021. REUTERS/Sumaya Hisham/File Photo
“So that’s the good news, it shows again that the vaccine is effective against severe disease and death,” she said.

With at least 70% of the South African population estimated to have been

exposed to COVID-19 over the past 18 months, high estimated levels of existing antibodies might skew the data.

“This could be a confounding factor for these hospital admission and severity indicators during this Omicron wave,” Ryan Noach, chief executive of Discovery Health, said in a briefing on the study. The analysis showed protection against hospital admission was maintained across all ages, from 18 to 79 years, with slightly lower levels of protection for the elderly. Protection against admission was also consistent across a range of chronic illnesses including diabetes, hypertension, hypercholesterolemia and other cardiovascular diseases.

REINFECTION RISK

The study concluded there was a higher risk of reinfection during the fourth wave than during previous waves and the risk of hospitalisation among adults diagnosed with COVID-19 was still 29% lower than during the country’s first wave last year.

敬請關注我們的新媒體帳號
Follow us on social media



Southern News
美南新聞



美南微信
公眾號



今日頭條
美國美南網



抖音
美國美南網



西瓜视频
美國美南網



Facebook Page
Southern News
美南新聞



Tik Tok ID:
Southern News Group



Instagram ID:
Southern News

WEA LEE'S GLOBAL NOTES

12/14/2021



Wea H. Lee
Wealee@scdaily.com

Chairman of International District Houston Texas

Publisher Southern Daily Wea H. Lee

Southern News Group Chairman / CEO
Chairman of International Trade & Culture Center
Republic of Guiana Honorary consul at Houston Texas

Nanjing Massacre Scars Of History



The Nanjing Massacre was an episode of mass murder and rape committed by Japanese imperial troops against the residents of Nanjing which at that time was the capital of China.

Over a period of six weeks Japanese army forces brutally murdered hundreds of thousands of people. About 80,000 women were sexually assaulted. An estimate of over 300,000 Chinese were killed.

The event remains as a continuous political issue between the two countries. Nanjing, the capital of China, was left in ruins. It took decades to rebuild the city.

On December 13, 1937, the first troops of Japan's Central China Front Army entered the city having "killing contests." Chinese soldiers were hunted down and killed by the thousands and left in mass graves. Entire families were massacred. Even the elderly and infants were targeted for execution.

Today when we look

back at history, how horrified we are of the war.

We need to memorialize these scars of history. We urge all politicians to learn how to avoid war.

We see that the world is now in chaos. We are having trouble in the Taiwan Straits and in the Ukraine. These political hotspots could be leading to war.



Southern DAILY Make Today Different

Editor's Choice



Braelyn Todd, 8, holds her dog Abner, a Yorkshire Terrier, as her parents help a family member clear debris from their destroyed home in the aftermath of a tornado in Mayfield, Kentucky. REUTERS/Adrees Latif



A water tower for the town is seen destroyed in the aftermath of a tornado at sunrise in Mayfield, Kentucky. REUTERS/Adrees Latif



Laura Croft searches through debris near the location where her mother and aunt were found deceased after tornadoes ripped through several U.S. states in downtown Dawson Springs, Kentucky. REUTERS/Jon Cherry



Miss Universe winner Miss India Harnaaz Sandhu reacts as the Miss Universe crown is placed on her head by Outgoing Miss Universe Andrea Meza of Mexico, at the Red Sea resort of Eilat, Israel. REUTERS/Ronen Zvulun



Divers work aboard the Danish cargo ship Karin Hoej which collided with the British cargo ship Scot Carrier between Ystad and Bornholm, on the Baltic Sea. Johan Nilsson/TT News Agency



James Strickland, 42, a houseless man, walks through the wreckage of his friend's home where he has been staying and guarding following a tornado in Mayfield, Kentucky. "I have only been able to take bits and pieces of it in," said James, "It hurts so much to see what was once a thriving beautiful town." REUTERS/Cheney Orr

BUSINESS

Trials Of The New COVID-19 Pill Reduced Hospitalizations And Deaths By 50% In People Recently Infected With The Coronavirus

Merck COVID-19 Pill Seen As ‘Huge Advance’ Raises Hope Of Preventing COVID-19 Deaths By 50 Percent

Compiled And Edited By John T. Robbins, Southern Daily Editor



Merck & Co. shows their new antiviral medication. Pharmaceutical company Merck & Co. announced Friday, that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use. Merck & Co. /AP

KEY POINTS

Merck says trials of its new COVID-19 pill reduced hospitalizations and deaths by 50% in people recently infected with the coronavirus. Merck will seek U.S. approval for pill as soon as possible. If approved, would be 1st oral antiviral COVID-19 drug Merck shares rally, some vaccine makers fall U.S. government to buy 1.7 mln courses at \$700 each

WASHINGTON — Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.

If cleared, Merck’s drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.

Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of

hospitalization and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease. Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck. The results were released by the company and have not been peer reviewed. Merck said it plans to present them at a future medical meeting.



The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. (Photo/REUTERS/Brendan McDermid)

An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. Company executives said they are in discussions with the Food and Drug Administration and plan submit the data for review in coming days.

“An oral antiviral that can impact hospitalization risk to such a degree would be game-changing,” said Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security.

Current treatment options include Gilead Sciences Inc’s (GILD.O) infused antiviral remdesivir and generic steroid dexamethasone, both of which are generally only given once a patient has already been hospitalized.

“This is going to change the dialogue around how to manage COVID-19,” Merck Chief Executive Robert Davis told Reuters.

Existing treatments are “cumbersome and logistically challenging to administer. A simple oral pill would be the opposite of that,” Adalja added.

The results from the Phase III trial, which sent Merck shares up more than 9%, were so strong that the study is being stopped early at the recommen-

dation of outside monitors. Shares of Atea Pharmaceuticals Inc (AVIRO.O), which is developing a similar COVID-19 treatment, were up more than 21% on the news. Shares of COVID-19 vaccine makers Moderna Inc (MRNA.O) were off more than 10%, while Pfizer (PFE.N) was down less than 1%.. Jefferies analyst Michael Yee said investors believe “people will be less afraid of COVID and less inclined to get vaccines if there is a simple pill that can treat COVID.”

Pfizer and Swiss drugmaker Roche Holding AG (ROG.S) are also racing to develop an easy-to-administer antiviral pill for COVID-19. For now, only antibody cocktails that have to be given intravenously are approved for non-hospitalized patients.

White House COVID-19 response coordinator Jeff Zients said on Friday that molnupiravir is “a potential additional tool... to protect people from the worst outcomes of COVID,” but added that vaccination “remains far and away, our best tool against COVID-19.”

“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr. Dean Li, vice president of Merck research. “When you see a 50% reduction in hospitalization or death that’s a substantial clinical impact.”

Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems. Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.



An experimental COVID-19 treatment pill called molnupiravir being developed by

Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Hand-out via REUTERS

A planned interim analysis of 775 patients in Merck’s study looked at hospitalizations or deaths among people at risk for severe disease. It found that 7.3% of those given molnupiravir twice a day for five days were hospitalized and none had died by 29 days after treatment. That compared with a hospitalization rate of 14.1% for placebo patients. There were also eight deaths in the placebo group. “Antiviral treatments that can be taken at home to keep people with COVID-19 out of the hospital are critically needed,” Wendy Holman, Ridgeback’s CEO, said in a statement.

The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to be given by IV or injection at hospitals or medical clinics, and supplies have been

stretched by the latest surge of the delta variant. Health experts including the top U.S. infectious disease expert Dr. Anthony Fauci have long called for a convenient pill that patients could take when COVID-19 symptoms first appear, much the way the decades-old flu medication Tamiflu helps fight influenza. Such medications are seen as key to controlling future waves of infection and reducing the impact of the pandemic. Merck’s pill works by interfering with an enzyme the coronavirus uses to copy its genetic code and reproduce itself. It has shown similar activity against other viruses.

The U.S. government has committed to purchase 1.7 million doses of the drug if it is authorized by the FDA. Merck has said it can produce 10 million doses by the end of the year and has contracts with governments worldwide. The company has not announced prices. Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.

Merck had planned to enroll more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients enrolled across Latin America, Europe and Africa. Executives estimated about 10% of patients studied were from the U.S. (Courtesy npr.com)

‘A HUGE ADVANCE’

Scientists welcomed the potential new treatment to help prevent serious illness from the virus, which has killed almost 5 million people around the world, 700,000 of them in the United States.



“A safe, affordable, and effective oral antiviral would be a huge advance in the fight against COVID,” said Peter Horby, a professor of emerging infectious diseases at the University of Oxford. The study enrolled patients with laboratory-confirmed mild-to-moderate COVID-19, who had symptoms for no more than five days. All patients had at least one risk factor associated with poor disease outcome, such as obesity or older age. Drugs in the same class as molnupiravir have been linked to birth defects in animal studies. Merck has said similar studies of molnupiravir – for longer and at higher doses than used in humans – indicate that the drug does not affect mammalian DNA.

Merck said viral sequencing done so far shows molnupiravir is effective against all variants of the coronavirus including the highly transmissible Delta, which has driven the recent worldwide surge in hospitalizations and deaths. It said rates of

adverse events were similar for both molnupiravir and placebo patients, but did not give details. Merck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, but men enrolled in its trials had to abstain from heterosexual intercourse or agree to use contraception. Women of child-bearing age in the study could not be pregnant and also had to use birth control. The U.S. drugmaker said it expects to produce 10 million courses of the treatment by the end of 2021.

Merck and partner Ridgeback Biotherapeutics said they plan to seek U.S. emergency use authorization for the pill as soon as possible and to make regulatory applications worldwide. The results from the Phase III trial, which sent Merck shares up more than 9%, were so strong that the study is being stopped early at the recommendation of outside monitors.

A planned interim analysis of 775 patients in Merck’s study looked at hospitalizations or deaths among people at risk for severe disease. It found that 7.3% of those given molnupiravir twice a day for five days were hospitalized and none had died by 29 days after treatment. That compared with a hospitalization rate of 14.1% for placebo patients. There were also eight deaths in the placebo group.



“Antiviral treatments that can be taken at home to keep people with COVID-19 out of the hospital are critically needed,” Wendy Holman, Ridgeback’s CEO, said in a statement.

The company has a U.S. government contract to supply 1.7 million courses of molnupiravir at a price of \$700 per course.

Davis said Merck has similar agreements with other governments, and is in talks with more. Merck said it plans a tiered pricing approach based on country income criteria.

The U.S. government has the option to purchase up to an additional 3.5 million treatment courses if needed, a U.S. health official told Reuters. The official asked to remain anonymous because they were not authorized to comment publicly on the contract. Merck has also agreed to license the drug to several India-based generic drugmakers, which would be able to supply the treatment to low- and middle-income countries.

“Molnupiravir is also being studied in a Phase III trial for preventing infection in people exposed to the coronavirus.

Merck officials said it is unclear how long the FDA review will take, although Dean Li, head of Merck’s research labs, said, “they are going to try to work with alacrity on this.” (Courtesy reuters.com)


Southern

DAILY

Make Today Different

COMMUNITY

The ‘Original’ COVID-19 Is Essentially Gone



This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases – Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. Viruses are constantly mutating, with coronavirus variants circulating around the globe. (Photo/NIAID-RML via AP)

Key Point

One infectious disease expert says the coronavirus that kicked off the pandemic has been ‘elbowed out of the way by the newer, more competitive strains’

Compiled And Edited By John T. Robbins, Southern Daily Editor

We all know the virus strains of alpha, beta and delta (in Prince-like fashion, the virus previously known as B.1.617.2). But do you know delta AY? And epsilon, gamma, iota, lambda, mu and theta? These variants of SARS-CoV-2 have all been logged in Southern California, and dozens more versions of the virus are circulating across the globe, battling for world domination like tiny Dr. Evils in an Austin Powers movie.

So, what happened to the “original” virus? The very first one that jumped from bats or labs — or wherever — into human beings who were immunologically powerless against it, eventually leading to the deaths of nearly 5 million people and grinding world economies to a near halt? Gone the “way of the dinosaurs, at least in humans,” said Dr. George Rutherford, professor of epidemiology and biostatistics at UC San Francisco.

“It has been displaced. Elbowed out of

the way by the newer, more competitive strains,” said Andrew Noymer, an epidemiologist and demographer at UC Irvine who studies infectious diseases.



The nocturnal intermediate horseshoe bat (Rhinolophus affinis), lives in caves and collect many diseases. Chinese researchers said they have found a batch of new coronaviruses in bats including one that may be the second-closest yet, genetically, to the virus that causes Covid-19 virus. (Shutterstock)

No one can say with 100% certainty that it’s gone, however, Noymer said. And Rutherford adds this caution: “God knows what’s going on in bats.”

Welcome to this friendly tutorial on viral mutation and why your life may depend upon it.

The SARS-CoV-2 that surfaced in Wuhan, China, in 2019 was likely not the original one, researchers say. And the version that swept through the United States in fall 2020 was already a mutation of the Wuhan version. And the one that steamrolled through the United States this summer was different still. Scientists have logged scores of versions of the virus that causes COVID-19 across the globe, and thanks to genetic sequencing, they can pinpoint which are circulating where. Sometimes, those genetic changes are of little consequence. Sometimes, they make the virus much better at infecting humans or evading treatments, and thus more dangerous.

The U.S. Centers for Disease Control and Prevention lists just the highly contagious delta B.1.617.2 and AY lineages as “variants of concern” here in the U.S., while the World Health Organization also includes alpha, beta and gamma on its “variants of concern” list.

Up and coming mutants to watch? The WHO is keeping its eye on lambda and mu.



Bats, rats and snakes were still being sold at an Indonesian market known for its ‘extreme’ wildlife offerings in February 2020, despite calls to take them off the menu over fears of COVID-19 coronavirus link. (Photo by RONNY ADOLFO BUOL/AFP via Getty Images)

Once upon a viral time

Scientists saw this coming.

Michael Buchmeier, an infectious disease researcher at UCI who has been studying coronaviruses for decades, takes us back some 20 years, to the original strain that sparked the SARS-1 outbreak in 2002-03.

Back then, only 12 other animal or human coronaviruses were known.

SARS-1 likely arose when two or more strains of bat coronaviruses combined

and jumped to palm civets, a masked animal that resembles a raccoon and is widely sold in live animal markets throughout Asia, he said. There, the virus was amplified and adapted, and eventually infected humans. It spread widely in China, Hong Kong, Taiwan and into Canada due to travel.

The fatality rate was 10%; for those over age 50, it was close to 50%.

There’s a key difference between SARS-1 and SARS-2, however: SARS-1 infections were essentially always symptomatic, making it far easier to spot and isolate outbreaks. SARS-2 can be spread by people with no symptoms, making it much harder to stop.

So, where is that virus now?

“SARS-1 as a unique pathogen appears to be ‘extinct’ in nature, but the conditions that produced it are still existent,” Buchmeier said.

“That is, the presence of coronaviruses that are present in wild bats, particularly in the horseshoe bats common throughout South Asia and China, and the husbandry of suitable amplifying hosts like the civet cat, the raccoon dog,

and now the pangolin and perhaps others capable of adapting the virus to more easily infect humans.”

Hundreds of viruses have been isolated from bats in Asia and worldwide, many of them coronaviruses that can recombine into dangerous pathogens, he said. A paper in Clinical Microbiology Reviews, published in 2007, issued a warning: “Coronaviruses are well known to undergo genetic recombination, which may lead to new genotypes and outbreaks. The presence of a large reservoir of SARS-CoV-like viruses in horseshoe bats, together with the culture of eating exotic mammals in southern China, is a time bomb. The possibility of the reemergence of SARS and other novel viruses from animals or laboratories and therefore the need for preparedness should not be ignored.” In 2015, another paper, in the journal Nature, warned of “a potential risk of SARS-CoV re-emergence from viruses

currently circulating in bat populations.” And, so, here we are. The precise origin of the virus that sparked the COVID-19 pandemic is still an official mystery, and may always be one. In addition to the widely embraced bat/wet market theory, there are suspicions that the virus may have leaked from a lab in Wuhan. The WHO has appointed a new, 25-member Scientific Advisory Group for the Origins of Novel Pathogens, with scientists from all over the world, to try to figure that part out.



A team from Kasetsart University collect bats at the Khao Chong Pran Cave for coronavirus research on September 12, 2020 in Ratchaburi, Thailand. (Photo by Lauren DeCicca/Getty Images)

Mutation nation

Each new infection is a new opportunity for the virus to mutate into something else. Maybe something less troublesome. Maybe something more troublesome.

“What’s worrying me about the upcoming winter wave is not so much the variants — it’s that we need more people vaccinated,” said UCI’s Noymer. “Seventy-five percent is not good enough to protect some age groups.”

Vaccination doesn’t prevent infection, but it’s very protective against severe disease, hospitalization and death, even with the highly contagious delta variant.

“The clear message is that as long as vaccination of populations remains incomplete and clearly effective social distancing and masking are not observed, we’re very likely to see more waves,” Buchmeier said.

Will SARS-CoV-2 mutate into something more lethal still? Crystal balls are cloudy, but many experts don’t expect that to happen. They do, however, expect it to remain in circulation as part of the “human virome” — the total collection of viruses in and on the human body — for a very, very long time.

Viral variants will continue to appear, and some may be more capable of spreading.

But even if we eventually make peace with this virus — as we have with the flu — threats loom. Buchmeier said that the precursors of SARS-CoV-1 and SARS-CoV-2 remain in bats, and may provide a reservoir for future cycles of human infection. (Courtesy ocregister.com)

美南國際電視 15.3 《美南時事通》

馬斯克影響力從地球到太空 獲選時代雜誌風雲人物!



（本報記者黃梅子）美國「時代雜誌」（Time）今天宣布，2021 年度風雲人物由影響力超越地球、甚至延伸到太空的電動車大廠特斯拉（Tesla）執行長暨創辦人馬斯克（Elon Musk）獲選。時代雜誌形容，今年 50 歲的馬斯克身為全球首富，名下卻沒有自己的房子，而且最近一直在變賣財產；他將許多衛星送入軌道，同時也懂得利用太陽的力量；他駕駛自己創造的汽車，但這輛車不需要汽油，甚至也不一定需要人類來駕駛。

此外，馬斯克所說的每句話，都被大批信徒奉為圭臬，只要他隨手一則推文，就能撼動股市。他在地球上呼風喚雨，卻夢想前往火星；他意誌堅定，同時又霸氣過人。

時代雜誌還說，對馬斯克而言，他的巨額財富只是自身能力的「附帶效果」。在攸關人類存續的各項領域

中，他不僅能看出、而且還能做到別人做不到的事。

馬斯克除了是特斯拉執行長，還是太空探索科技公司（SpaceX）創辦人兼執行長，同時領導大腦晶片公司 Neuralink 和基礎建設公司鑽洞公司（The Boring Company）。

特斯拉是電動車業龍頭，近年股價飛漲，讓馬斯克的資產價值飆升。他的太空探索科技公司致力多項太空計畫，除積極參與美國太空任務，也推展太空旅遊，以及發射低軌衛星的「星鏈」計畫（Starlink）。

馬斯克的身價逼近 2970 億美元（約新臺幣 8 兆元），在推特上有超過 6600 萬粉絲。10 日他還發文問網友：「我想辭掉工作，當個全職網紅，你們認為如何？」

時代雜誌同日也公布 2021 年度英雄，包括 4 位創造奇蹟的疫苗科學家，他們分別是柯貝特（Kizzmekia Corbett）、葛蘭姆（Barney Graham）、卡林科（Katalin Kariko）與魏斯曼（Drew Weissman）。

去年獲選年度風雲人物的是現任美國總統拜登（Joe Biden）和副手賀錦麗（Kamala Harris）。當時拜登在投票率創新高的歷史性總統大選中擊敗對手—前總統川普，並於今年 1 月 20 日就職，成為美國第 46 位總統。

時代雜誌每年都會選出年度風雲人物，無論獲選人或團體的影響力是正面或負面，都對過去 12 個月的時事及世界脈動具有重大影響。

時代年度風雲人物最後會由雜誌編輯群定奪；網路票選結果則可讓人一窺讀者認為何人對今年事件最有影響力。

時代雜誌本月 7 日公布 2021 年風雲人物讀者票選結果，由巴西總統波索納洛（Jair Bolsonaro）勝出。這位備受爭議的領導人將於 2022 年競選連

任，但他的經濟措施面臨日益高漲的批評聲浪，他也因刻意淡化 COVID-19（2019 冠狀病毒疾病）嚴重性和對疫苗抱持懷疑態度，受到政壇、法院和公衛專家的廣泛批評。

24 歲美國體操天后拜爾絲（Simone Biles）則於 9 日獲選時代雜誌（TIME）年度運動員，稱她在東京奧

運的退賽之舉，凸顯運動員心理健康問題，激發社會各界更廣泛的討論。

請關注美南國際電視 15.3 頻道《美南時事通》，也可以通過 iTalkBB 平臺收看。美南新聞網站 scdaily.com，也可以在 youtube 上搜索 Stv15.3 Houston，訂閱美南新聞頻道，隨時收看美南國際電視的節目。



UnitedHealthcare®

聯合健康保險



為民眾帶來更健康的生活

維他命知多少？

根據國立衛生研究院指出，維他命(又稱維生素)是人體生存和保持健康所需的主要營養素之一。但在您購買一瓶綜合維他命並將其納入您的日常所需之前，您應該知道下列事實：

事實 #1 維他命補充劑可以是增加維他命攝取量的便利方法，但從食物中攝取維他命會比藥丸更好。原因是營養豐富的食物能提供額外的健康益處，例如纖維。研究指出，一份哈密瓜可以提供維他命A、C和K，以及鈣、鎂、鉀和多種抗氧化劑。大多數年長者可從食物中獲取所需的營養，但如果您不常進食健康、營養豐富的食物，明智的做法是告訴您的醫生或註冊營養師，由他推薦一種特定的維他命補充劑來幫助彌補您可能缺乏的維他命。

事實 #2 必需的維他命共有13種，而每種維他命發揮著不同的作用，以保持身體處於最佳狀態，因此，對您的整體健康至關重要。例如，維他命C攝入不足可導致貧血。以下是每種維他命功能的概述：

- 維他命A：幫助形成和維持健康的牙齒、骨骼和皮膚
- 維他命C：促進牙齒和牙齦健康並加快傷口癒合
- 維他命D：幫助身體吸收鈣
- 維他命E：幫助身體製造紅血球
- 維他命K：使血液粘在一起所必需的
- 維他命B1(硫胺素)：幫助細胞將碳水化合物轉化為能量
- 維他命B2(核黃素)：對人體生長和紅血球的形成很重要
- 維他命B3(菸酸)：幫助維持健康的皮膚和神經
- 維他命B5(泛酸)：是幫助食物新陳代謝和產生激素所必需的
- 維他命B6：幫助形成紅血球並維持大腦功能
- 維他命B7(生物素)：是在蛋白質和碳水化合物的代謝中所必需的
- 維他命B9(葉酸)：幫助形成紅血球並且是產生DNA所必需的
- 維他命B12(氰鈷胺)：對新陳代謝和維持中樞神經系統很重要

事實 #3 您可以按照建議的每日攝取量來確保攝取足夠的維他命。建議的每日攝取量可在食品包裝上的營養成分標籤找到。對於即食和生食的食物（例如熟食肉類和新鮮水果），可瀏覽 fdc.nal.usda.gov 並輸入食物類型。

請記住，根據國立衛生研究院指出，建議的每日攝取量是為了“大多數健康的人”的營養需求而制定。您的醫生和/或營養師可能針對您的個別健康需求提供更具體的建議。

事實 #4 由於飲食在維他命攝取中起著重要作用，因此盡量多進食營養豐富的食物是明智的做法。以下是一些維他命的食物來源。(哈佛醫學院的清單列有更多食物資料。
https://www.health.harvard.edu/staying-healthy/listing_of_vitamins)

瑞士芝士	維他命A	含脂肪魚類	維他命D
西瓜	維他命B1	堅果	維他命E
蘑菇	維他命B3	番茄汁	維他命B9
西蘭花	維他命C	鱈鰵(又名牛油果)	維他命B5

與您的醫生討論您可能需要或可以嘗試的維他命，讓您在下次購物時能做出最佳選擇。

© 2021 United HealthCare Services, Inc. 保險承保透過或經由聯合健康保險公司、紐約聯合健康保險公司或其關聯機構所提供。行政服務則由聯合健康保險公司、聯合健康保險服務公司或其關係機構所提供。保險產品則由聯合健康保險公司承保。
Y0066_200106_125646_C_CT

立即關注聯合官方帳號



華語查詢專線：
1-866-868-8988
聽力語言殘障專線：711

休士頓資訊中心：
10613 Bellaire Blvd., Suite A-250
Houston, TX 77072
(Saigon Houston Plaza二樓)

www.uhcAsian.com